The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the tom 40 that's next the e4 is really can influence in my opinion i believe i'm not certain but i believe that the different tom40 chain length or whatever it is one e4 can behave one way and another e4 can have a lower or high or higher risk depending on the gene next to it
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
those who have apoe2 are protected from getting alzheimer's disease so the two four carriers sometimes behave as four sometimes behave as two and this may have to do with how well these proteins are getting expressed inside the cells and potentially other genes as well like tom 40 or fgf and things like that that seem to also play a role here
2 is supposed to be protective those who have apoe2 are protected from getting alzheimer's disease